GL1X · GenesisL1 explorer

UniProt P39478

30S ribosomal protein S2 (P39478)

30S ribosomal protein S2 (UniProt P39478): 11 experimental structures and 1 predicted model on GenesisL1, 1 ligand bound, 5 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.

UniProt
P39478
Protein
30S ribosomal protein S2
Experimental structures
11
Predicted models
1
Ligands
1
Pockets
5 · 4 records with a druggable one

Structures

12 records of P39478 in the MolNFT archive: 11 experimental, 1 predicted.

EntryTitleMethodChainsLigandsPockets
8HKXCryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2P——
8HKYCryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8HKZCryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8HL1Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8HL2Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK1 (best 0.85)
8HL3Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8HL4Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8HL5Cryo-EM Structures and Translocation Mechanism of Crenarchaeota Ribosomeelectron microscopyAS2PUNK—
8WKPStructural basis of translation inhibition by a valine tRNA-derived fragmentelectron microscopyAS2PUNK1 (best 0.86)
8WQ2Structural basis of translation inhibition by a valine tRNA-derived fragmentelectron microscopyAS2PUNK1 (best 0.80)
8WQ4Structural basis of translation inhibition by a valine tRNA-derived fragmentelectron microscopyAS2PUNK2 (best 0.78)
P39478AlphaFold monomer V2.0 prediction for 30S ribosomal protein S2 (P39478)predictedA——

Ligands

  • UNK · Unknown · in 10 records

Experiment against prediction

Elsewhere

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.